°Ç¼±Àº ¾î¶² ÁúȯÀΰ¡¿ä?

1. ÇǺΠ¼Ó¿¡¼­ ÀϾ´Â ÀÏ 1,3,11,12

°Ç¼± ÇǺΠ¼Ó¿¡´Â ¼¼Æ÷ÀÇ ºñÁ¤»óÀûÀΠȰµ¿ÀÌ ÀϾ°í ÀÖ½À´Ï´Ù.

°Ç¼± ¹ßº´ ¿øÀÎÀº ¸íÈ®ÇÏ°Ô ¹àÇôÁöÁö ¾Ê¾Ò½À´Ï´Ù.
ÇÏÁö¸¸ Á¤»ó ÇÇºÎ¿Í ´Þ¸® °Ç¼± ÇǺο¡¼­´Â °¢ÁúÀ» ¸¸µé¾î³»´Â ¼¼Æ÷°¡ Áö³ªÄ¡°Ô ÀÚ±ØÀ» ¹Þ¾Æ ºü¸£°Ô Áõ°¡ÇÕ´Ï´Ù.
ÀÌ·Î ÀÎÇØ ºñµë°ú °°Àº °¢ÁúÀÌ °ã°ãÀÌ ½×ÀÌ°Ô µË´Ï´Ù.

2. °¡Àå ÈçÇÑ ÆÇ»ó°Ç¼±

-
°Ç¼±ÀÇ À¯Çü¿¡´Â ÆÇ»ó, ³óÆ÷¼º, °£ÂûºÎÀ§, ¹°¹æ¿ï, È«ÇǼº °Ç¼± µîÀÌ Àִµ¥ ÀÌ Áß ÆÇ»ó°Ç¼±ÀÌ ÀüüÀÇ 80-90%·Î °¡Àå ÈçÈ÷ ¹ßº´ÇÕ´Ï´Ù. 1
-
ÆÇ»ó °Ç¼±Àº Àº¹é»öÀÇ ºñ´ÃÀÌ ºÓÀº »öÀÇ ÆÇ»ó ÇüÅ·ΠÇǺθ¦ µ¤´Â °ÍÀ¸·Î, ¹«¸­, ÆÈ²ÞÄ¡, µî ÇϺÎ, µÎÇÇ µî¿¡ ¹ß»ýÇÕ´Ï´Ù. 4

3. °Ç¼±ÀÇ À¯º´·ü 1,3

¿ì¸®³ª¶ó °Ç¼± ȯÀÚ´Â ¾à 20~30¸¸¸íÀ¸·Î Ãß»êµÇ¸ç 20´ë¿¡ °¡Àå ¸¹ÀÌ ¹ßº´ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.(2011³â °Ç°­º¸Çè½É»çÆò°¡¿ø ÀÚ·á ±âÁØ)

4. °Ç¼±ÀÇ ÇÕº´Áõ ¹× µ¿¹Ý Áúȯ

-
ÁßÁõÀÇ °Ç¼± ȯÀÚ¿¡¼­ »ç¸Á·üÀÇ Áõ°¡°¡ °üÂûµÈ ¿¬±¸ °á°ú°¡ ÀÖ½À´Ï´Ù. 9
-
¸é¿ªÁúȯÀÎ °Ç¼±À» ¾Î°í Àִ ȯ½ÀµéÀº ´ç´¢º´, °Ç¼±¼º °üÀý¿°, ½ÉÀå Áúȯ, ºñ¸¸, ½ÅÁø´ë»çÀå¾Ö, ½ÉÀåÇ÷°ü°è Áúº´, Á¤½Å Áúȯ, ¾Ï(¸²ÇÁÁ¾) µîÀÇ ¿©·¯ ÁúȯÀÌ µ¿¹ÝµÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. 5,6,7,8,9
-
¹®Çå¿¡ µû¸£¸é ½ÇÁ¦ °Ç¼±È¯ÀÚ 10¸íÁß 3¸íÀº °Ç¼±¼º °üÀý¿°À» ¾Î°í ÀÖ´Ù´Â º¸°í°¡ ÀÖ½À´Ï´Ù. 10 (2012³â, °Ç¼±È¯ÀÚ 949¸í ´ë»ó Á¶»ç ±âÁØ)

°Ç¼± Àü¹®ÀÇÀÇ Áø´Ü¿¡ µû¸¥ ÀûÀýÇÑ Ä¡·á°¡ Áß¿äÇÕ´Ï´Ù

°Ç¼±ÀÇ ½É°¢µµ, ȯÀÚÀÇ °Ç°­ »óŵîÀ» Á¾ÇÕÀûÀ¸·Î °í·ÁÇÏ¿© Ä¡·á¹æ¹ýÀÌ °áÁ¤µË´Ï´Ù. 1,2

°Ç¼±ÀÇ ½É°¢µµº° Ä¡·á¹ý ±×·¡ÇÁ

º» ³»¿ëÀº ÀÌÇØ¸¦ µ½±â À§ÇÑ Âü°í ÀÚ·áÀÏ »ÓÀÌ¸ç °³º°È¯ÀÚÀÇ Áõ»ó°ú Áúº´¿¡ ´ëÇÑ ÆÇ´ÜÀ» À§Çؼ­´Â Àü¹®ÀÇÀÇ Áø´ÜÀÌ ¹Ýµå½Ã ÇÊ¿äÇÕ´Ï´Ù.

±¹³» Àüü °Ç¼± ȯÀÚ Áß ¾à 85%´Â
Á¦´ë·Î µÈ Ä¡·á¸¦ ¹Þ°í ÀÖÁö ¾Ê½À´Ï´Ù.
Àü¹®ÀÇ¿Í »ó´ãÀ» °ÅÃÄ
¿Ã¹Ù¸£°í Áö¼ÓÀûÀ¸·Î °ü¸®
ÇÑ´Ù¸é
Áõ»ó ¿ÏÈ­´Â ¹°·Ð
Àç¹ßµµ ´ÊÃâ ¼ö ÀÖ½À´Ï´Ù.1

»ýȰ ¼Ó °Ç¼± °ü¸®¹æ¹ýÀº ¹«¾ùÀÌ ÀÖ³ª¿ä? 1,2

ÀÚÁÖ ¹¯´Â Áú¹®

Q
°Ç¼±µµ À¯ÀüÀÌ µÇ³ª¿ä? 2
A
ºÎ¸ð Áß ÇÑ ºÐÀÌ °Ç¼±À̶ó¸é ¾ÆÀÌ¿¡°Ô °Ç¼±¿¡ °É¸®±â ½¬¿î À¯ÀüÀÚ°¡ Àü´Þ µÉ ¼ö ÀÖÀ¸³ª ÀÌ·± °æ¿ì¿¡µµ È®·üÀº 20%°¡ ¾ÈµË´Ï´Ù. ºÎ¸ð ¸ðµÎ°¡ °Ç¼±È¯ÀÚ¶óµµ Àڳ࿡°Ô ¹ßº´ÇÒ È®·üÀº 50%¿¡ ¹ÌÄ¡Áö ¸øÇÑ´Ù´Â º¸°í°¡ ÀÖ½À´Ï´Ù. ºÎ¸ð°¡ Á¤»óÀÌ¶óµµ Àڳడ °Ç¼±¿¡ °É¸± ¼ö ÀÖ½À´Ï´Ù.
Q
°Ç¼±ÀÌ ¹ß»ýÇÏ´Â ¿¬·É´ë°¡ Á¤ÇØÁ® ÀÖ³ª¿ä? 1
A
°Ç¼±Àº ¾î´À ³ªÀÌ¿¡¼­³ª ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ³ªÀ̺°·Î´Â 20´ë, 10´ë, 30´ë ÀÇ ¼øÀ¸·Î ³ô°Ô ³ªÅ¸³³´Ï´Ù.
Q
ºñ¸¸°ú °Ç¼±ÀÌ °ü·Ã¼ºÀÌ ÀÖ³ª¿ä? 1
A
Áö¹æ¿¡¼± ¿°ÁõÀ» ¾ÇÈ­½ÃŰ´Â ¹°ÁúÀÌ ¸¹ÀÌ ºÐºñµÇ¹Ç·Î °Ç¼±¿¡ ÀÇÇÑ ¿°ÁõÀ» Áö¼Ó ȤÀº ¾ÇÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ °úüÁß È¤Àº ºñ¸¸ÀΠȯÀÚ¿¡°Ô¼­ °Ç¼±Áõ»óÀÌ ´õ ½ÉÇÏ°Ô ³ªÅ¸³­´Ù´Â ¿¬±¸°á°úµµ ÀÖ½À´Ï´Ù. ¹Ý´ë·Î üÁßÀ» ±Þ°ÝÈ÷ ÁÙÀÌ°í ³ª¼­ ¿À·£ ±â°£ Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´ø °Ç¼±ÀÌ È£ÀüµÇ¾ú´Ù´Â º¸°íµµ ÀÖÀ¸¹Ç·Î °Ç¼± ȯÀÚ´Â ÀûÁ¤ÇÑ Ã¼ÁßÀ» À¯ÁöÇÏ´Â °ÍÀÌ ÇÊ¿äÇÕ´Ï´Ù.
Q
°Ç¼±ÀÇ »óÅ¿¡ µû¶ó Ä¡·á¸¦ Áß´ÜÇØµµ µÇ³ª¿ä? 1, 2
A
°Ç¼±Àº ¿ÏÄ¡µÇÁö´Â ¾ÊÀ¸¹Ç·Î Áõ»óÀÌ ÁÁ¾ÆÁ³´Ù ³ªºüÁö´Â °ÍÀ» ¹Ýº¹Çϸç Àç¹ßÇÕ´Ï´Ù. ²ÙÁØÇÑ Ä¡·á¿Í »ýȰ ¼Ó °ü¸®¸¦ ÅëÇØ °Ç¼±ÀÌ Àç¹ßµÇÁö ¾Êµµ·Ï ÁÖÀÇÇÕ´Ï´Ù.

ÀÚÀÇÀûÀÎ ÆÇ´ÜÀ¸·Î Ä¡·á¸¦ Áß´ÜÇØ¼­´Â ¾ÈµË´Ï´Ù. Ä¡·á °ü·ÃÇÑ ¸ðµç »çÇ×µéÀº ÁÖÄ¡ÀÇ ¼±»ý´Ô°ú »ó´ãÀ» ÅëÇØ °áÁ¤Çϼ¼¿ä
Q
°Ç¼±µµ Àü¿°ÀÌ µÇ³ª¿ä? 1
A
°Ç¼±Àº Àü¿°µÇÁö ¾Ê±â ¶§¹®¿¡ ħ±¸, ÀÇ·ù ¹× °³ÀÎ À§»ý¿ëǰÀ» ¼Òµ¶Çϰųª ºÐ¸®Çؼ­ »ç¿ëÇÏ½Ç ÇÊ¿ä´Â ¾ø½À´Ï´Ù.

References

1.
´ëÇѰǼ±ÇÐȸ. http://kspder.or.kr
2.
±¹°¡°Ç°­Á¤º¸Æ÷ÅÐ_°Ç¼±. http://health.mw.go.kr/HealthInfoArea/HealthInfo/View.do?idx=110
3.
À±ÀçÀÏ. Çѱ¹ÀÎÀÇ °Ç¼±. ´ëÇÑÇǺΰúÇÐȸÁö 2012;50(5):387¡­402
4.
National Psoriasis Foundation. Available at: http://www.psoriasis.org/about-psoriasis/types. Accessed March 6, 2018.
5.
Farley E et al. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011 Feb;146(1):9-15.
6.
Krueger JG, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results for a 1998 National Psoriasis Foundation patient membership survey. Arch Derm. 2001; 137:280-284
7.
Ljosaa TM, Mork C, Stubhaug A, et al. Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. J Eur Acad Dermatol Venereol. 2012;26;29-35.
8.
Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586-92.
9.
Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493-9.
10.
Philip J. Mease, et al. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs (2014) 74:423-441
11.
Jin Young Lee et al. Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database. Ann Dermatol Vol. 29, No. 6, 2017 : 761-767
12.
Ju Hee Han et al. Epidemiology and Medication Trends in Patients with Psoriasis: A Nationwide Population-based Cohort Study from Korea. Acta Derm Venereol 2018; 98: 396-400